StockNews.AI
XBIO
StockNews.AI
159 days

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

1. XBIO presented promising preclinical data on DNase I enhancing CAR-T therapy. 2. Study at SITC 2025 shows DNase I improves T cell functionality in melanoma.

3m saved
Insight
Article

FAQ

Why Bullish?

The positive preclinical data can increase investor confidence, potentially boosting stock prices as seen with similar biotech announcements historically, which led to short-term price rallies.

How important is it?

The innovative approach of co-administering DNase I with CAR-T therapy tackles significant issues in cancer treatment, which is highly relevant for XBIO's focus, raising its potential for successful outcomes and investment appeal.

Why Short Term?

The presentation's immediate visibility at a major conference can lead to price movements, with investor reactions typically occurring shortly after such events as evidenced by past data releases in biotech.

Related Companies

CAR-TT cellB16AMGN
Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting Findings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not only facilitates increased T cell infiltration but also restores T cell functionality, paving the way for more effective cancer treatment strategies FRAMINGHAM, MA / ACCESS Newswire / March 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster titled, " DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma ," was presented on behalf of the Company by Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute, at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.

Related News